Lion Biotechnologies reports first patient dosed in second cohort of LN-144 phase 2 trial
Lion Biotechnologies announced the first patient was dosed in the second cohort of its ongoing Phase 2 trial of LN-144 for treatment of patients with metastatic melanoma. This cohort utilizes the company's generation 2 manufacturing process which includes cryopreservation of the outbound products. May 19, 2017